Another busy day so I have to keep this very short as I am trying to squeeze this in between meetings. In general, the sector seems to be doing fine.
A lot of news to cover and I want to get to it all, so maybe a little less detail and more topics today and I will circle back to.
It is a busy day so I am going to try and keep this short but every time I write that it seems like I write the same amount if.
Happy merger Monday- well, happy Monday at least. The sector is off to a good start this week despite another dearth of deals this morning. It does worry me a.
The market is choppy this morning so it is difficult to read anything into the price action. I am growing slightly more constructive on the near term of the sector.
I have not had a chance to follow the market last week, so I do not really have a sense how the sector is doing. It looks like it has.
It looks like we have all survived the great biotech sell off of 2015. To be honest, I am not sure this really counts as a sell off (yet). We.
A rough start to morning for the sector with a biotech bubble article in the WSJ not helping. There was nothing new but the headline is the headline (it also.
A weak start to the week but it is also a continuation from the weak ending of last week. Everyone is waiting for a pullback. The bulls expect a moderate.
Some early weakness but I also suspect today is going to be fairly volatile with the Fed weighing in later this afternoon. So I am really not going to read.